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Background: Population aging is expected to result in a substantial additional burden on healthcare resources in the near future. We aimed to assess the
current and future impact of aging on direct healthcare costs (DHC) attributed to inflammatory bowel disease (IBD).
Methods: Patients with IBD from a Dutch multicenter cohort filled out 3-monthly questionnaires for 2 years. Elderly ($60 yr) and younger patients
(18–60 yr) IBD were analyzed for differences in 3-monthly DHC, productivity losses, and out-of-pocket costs. Prevalence rates were obtained from
a health insurance database. Estimates of annual DHC and prevalence rates were applied to the total Dutch adult population in 2011 and then projected to
2040, using predicted changes in population demography, prices, and volume.
Results: IBD-attributable DHC were lower in elderly than in younger patients with IBD with respect to 3-monthly DHC (€359 versus €978, P , 0.01),
productivity losses (€108 versus €456, P, 0.01), and out-of-pocket costs (€40 versus €57, P, 0.01). Between 2011 and 2040, the percentage of elderly IBD
patients in the Netherlands has been projected to rise from 24% to 35%. Between 2011 and 2040, DHC of the total IBD population in the Netherlands are
projected to increase from €161 to €661 million. Population aging accounted for 1% of this increase, next to rising prices (29%), and volume growth (70%).
Conclusions: Population aging has a negligible effect on IBD-attributable DHC of the IBD population in the near future, because the average costs
incurred by elderly patients with IBD are considerably lower than those incurred by younger patients with IBD.
(Inflamm Bowel Dis 2014;20:637–645)
Key Words: elderly persons, inflammatory bowel disease, healthcare costs, aging
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on
the journal’s Web site (www.ibdjournal.org).
Received for publication November 26, 2013; Accepted December 19, 2013.
From the 1Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, the Netherlands 2Julius Center for Health Sciences and Primary
Care, University Medical Center Utrecht, Utrecht, the Netherlands; 3Agis Health Insurance, Amersfoort, the Netherlands; 4Department of Gastroenterology and Hepatology, VU
University Medical Center, Amsterdam, the Netherlands; 5Department of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, the Netherlands;
6Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands; 7Department of Gastroenterology and Hepatol-
ogy, Maastricht University Medical Center, Maastricht, the Netherlands; 8Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, the
Netherlands; 9Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands; 10Department of Gastroenterology and Hepatology,
Erasmus University Medical Center, Rotterdam, the Netherlands; 11Department of Gastroenterology and Hepatology, Slingeland Hospital, Doetinchem, the Netherlands;
12Department of Gastroenterology and Hepatology, Orbis Medical Center, Sittard, the Netherlands; 13Department of Gastroenterology and Hepatology, Diaconessenhuis,
Leiden, the Netherlands; 14Department of Gastroenterology and Hepatology, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands; 15Department of Gastroenterology
and Hepatology, St. Antonius Hospital, Nieuwegein, the Netherlands; 16Department of Gastroenterology and Hepatology, Reinier de Graaf Groep, Delft, the Netherlands; and
17Department of Gastroenterology and Hepatology, Meander Medical Center, Amersfoort, the Netherlands.
All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. A. van Bodegraven has acted as a consultant for Abbvie and
MSD and received payments for lectures from Abbvie and Ferring. H. H. Fidder has acted as a consultant for Abbvie. D. J. de Jong has acted as a consultant for Synthon
Netherlands and received payments for lectures from Abbvie, Ferring, and MSD. C. Y. Ponsioen has acted as a consultant for Abbvie and received payments for lectures from
Ferring and MSD. A. E. van der Meulen-de Jong has acted as consultant for Abbvie. M. Pierik has acted as a consultant MSD and received payments for lectures from MSD,
Falk Pharma, Abbvie and Ferring. C. J. van der Woude has acted as a consultant for Abbvie, Ferring, Shire, and MSD and received payment for lectures from Abbvie, Falk
Pharma and MSD. B. Oldenburg has received payments for lectures from Ferring and acted as a consultant for Abbvie and MSD.
Supported by an unrestricted grant from Abbvie.
Reprints: Mike van der Have, MD, Department of Gastroenterology and Hepatology, University Medical Center Utrecht, PO Box 85500, Utrecht 3500 GA, the
Netherlands (e-mail: M.vanderhave@umcutrecht.nl).
Copyright © 2014 Crohn’s & Colitis Foundation of America, Inc.
DOI 10.1097/01.MIB.0000442677.55051.03
Published online 10 February 2014.
Inflamm Bowel Dis  Volume 20, Number 4, April 2014 www.ibdjournal.org | 637
I nflammatory bowel disease (IBD), encompassing Crohn’s dis-ease (CD) and ulcerative colitis (UC), is one of the most prev-
alent chronic gastrointestinal diseases in the Western world.
Extrapolating the highest IBD prevalence rates to the
populations of Europe and North America indicates that there
were 3.7 million Europeans and 1.5 million North Americans
diagnosed with IBD in 2011, accounting for €17.9 and €7.4
billion annual direct healthcare costs (DHC), respectively.1–4
Currently, 16% to 27% of patients with IBD are older than
60 years, hereafter referred to as “elderly patients with IBD.”5
This subpopulation will expand as a result of the aging of the
baby boom generation.
Eurostat estimated that in Europe, the elderly population
would increase by 50%, from 116 million in 2010 to 175 million
in 2040.6 According to a recent survey of U.S. hospital dis-
charges, elderly patients with IBD accounted for a disproportion-
ate number of hospitalizations and had a higher postoperative
morbidity and mortality compared with younger patients.7,8
Therefore, the growing subpopulation of elderly patients with
IBD may increasingly burden healthcare resources.
In an era of budgetary constraints, more data on the
economic impact of IBD are required for proper allocation of the
limited healthcare resources. These data allow healthcare pro-
viders, policy makers, and clinicians to create a Pareto optimum
that is defined in economics as a reallocation of resources for the
benefit of all individuals.9
Previous cost-of-illness studies were mainly limited to
single centers, reported only DHC, and were conducted in
a prebiological era or relied on mathematic modeling.10–16 There-
fore, we initiated the “Costs of Inflammatory bowel disease in the
Netherlands” or “COIN” study in 2010.4 We used the COIN
database to compare the IBD-attributable DHC (DHC-IBD) and
productivity losses of elderly patients with IBD with those of
younger patients with IBD. Based on these data, we estimated
the 2011 DHC-IBD of the total adult IBD population in the
Netherlands and projected those to 2040.
MATERIALS AND METHODS
Patient Population
Details on the patient population are available elsewhere.4
Briefly, adult patients with both CD and UC from 7 general and 7
university hospitals were identified between 2007 and 2010, using
Diagnosis-Treatment-Combination codes. Diagnosis-Treatment-
Combination codes are based on the International Classification
of Disease, Ninth Revision17,18 and have been found to reliably
identify patients with IBD.19,20 In accordance with previous stud-
ies,5,7 patients $60 years were defined as “elderly patients with
IBD,” whereas those,60 years were defined as “younger patients
with IBD.” The study was centrally approved by the Medical
Ethics Committee of the University Medical Center Utrecht,
Utrecht, the Netherlands.
Study Protocol and Measurements
A secured web-based questionnaire was developed to obtain
baseline characteristics and 3-monthly cost data during 2 years of
follow-up. Demographic characteristics included sex, age, age at
diagnosis, education level, work status, family history, and smoking
status. Clinical characteristics included subtype of IBD, disease
duration and localization, penetrating disease course (perianal or
other fistula), stoma or pouch, and clinical disease activity. Clinical
disease activity was measured by the well-validated Short Crohn’s
Disease Activity Index21 and the Modified Truelove andWitts Sever-
ity Index22,23 for patients with CD and UC, respectively. Finally,
quality of life was measured by the EQ-5D23,24 and the IBDQ-32.25,26
DHC-IBD, Productivity Losses, and Out-of-
pocket Costs Attributable to IBD
DHC-IBD were obtained and classified as: (1) outpatient
visits, including the number of outpatient physician consultations;
(2) diagnostic procedures, including endoscopies and radiological
examinations; (3) medication use, including IBD-specific drugs
(mesalazine, steroids, immunosuppressants, and anti-TNFa anti-
bodies); (4) stoma-related costs; (5) IBD-related hospitalizations,
defined as the number of days hospitalized; and (6) IBD-related
surgeries, including intestinal resections and perianal operations.
In line with the Dutch guidelines for economic evaluations,
patient’s costs were calculated by multiplying self-reported units
of resource utilization by their unit costs.27
To assess productivity losses, we used sick leave of patients
and their caregivers from both paid and unpaid work as outcome
measure (absenteeism). Employed patients, partially disabled
patients with a paid job, and patients with an unpaid job (voluntary
work) reported the number of sick leave days within the previous
3 months. In addition, patients were asked to report whether their
caregivers were absent from paid work to take care of them, and if
so, for how many days. Hours of work absence (paid and unpaid)
of patients and caregivers were multiplied with the corresponding
unit prices as reported previously.4
Patients reported IBD-related out-of-pocket costs within the
previous 3 months, including patient’s deductibles for healthcare
insurance, over-the-counter drugs (vitamins, antidiarrheals, anal-
getics, probiotics, and minerals), travel costs, and subscriptions of
patient organizations. More details on the calculation method are
provided elsewhere.4
Nonresponders
As reported previously,4 there were no statistical differen-
ces between responders and nonresponders from 1 participating
center with regard to demographic (age, sex) and clinical charac-
teristics (disease duration, penetrating disease course, and abdom-
inal surgery in the past).
Projection of Prevalence Rates and DHC-IBD
of IBD
The projections were made as follows. First, IBD preva-
lence rates and annual DHC-IBD per person were generated for
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each age- (18–39, 40–59, and $60 yr), sex-, and IBD subtype-
specific group. The prevalence rate for each age-, sex-, and IBD
subtype-specific group was estimated by dividing the number of
patients with IBD by the total number of policy holders of the Agis
Health Insurance Company28 registered in July 1, 2011 and were
conservatively assumed to remain constant between 2011 and 2040.
Then, these prevalence rates were applied to the Census projections
of population counts for the years 2011 to 2040 to generate the total
IBD population for the years 2011 to 2040.29 Finally, the DHC-IBD
per person per 3 months were multiplied by 4 and by the corre-
sponding number of patients with IBD of the above-mentioned
groups to generate the total annual DHC-IBD of the IBD pop-
ulation for the years 2011 to 2040 (see Table, Supplemental
Digital Content 1, http://links.lww.com/IBD/A404).
In our base-case analysis, we projected the DHC-IBD of
the total IBD population from 2011 to 2040, taking into account
the cumulative effects of population aging, rising prices, and
volume growth (increased healthcare utilization) on the DHC-
IBD. Prices and volume of overall healthcare expenditure were
assumed to increase at the same rate for the next 30 years:
averaging an annual rate of 4.9% (2.2% due prices; 2.7% due
to volume). But as the increase in volume is debatable, we
conducted a scenario analysis, in which we only accounted for
the effects of population aging and rising prices (2.2%) on the
DHC-IBD.30,31
Finally, one-way sensitivity analyses were performed,
varying IBD prevalence rates and mean DHC-IBD of each age-,
sex-, and IBD subtype-specific group, using the lower and upper
ends of the 95% confidence interval (CI), to assess the uncertainty
of the projected DHC-IBD between 2011 and 2040. The pro-
jection method is described in full detail in Data, Supplemental
Digital Content 2, http://links.lww.com/IBD/A405.
Statistical Analysis
Data analyses were performed using SPSS 20.0 and SAS
9.2. Descriptive statistics were used to characterize patients with
both CD and UC according to their age. Mean and medians were
reported with an SD and an interquartile range, respectively.
Comparisons between elderly versus younger IBD were analyzed
with Student’s t test for continuous variables and x2 or Fisher’s
exact test for dichotomous variables.
Costs were expressed as mean costs with 95% CI
estimated using nonparametric bootstrap sampling. To iden-
tify cost drivers of high healthcare costs, we included
demographic, clinical, and treatment-related characteristics
into a 2-part mixed model. This model takes into account that
cost data are right-skewed with a substantial proportion of
zero values and consists of 2 parts: (1) a generalized linear
mixed model assessing the odds of costs being positive and (2)
a linear mixed model with log-normal link assessing the height
of costs given that costs were actually incurred. To account for
repeated measures within subjects, a random intercept was




In total, 3015 patients with IBD filled out the baseline
questionnaire, including 1551 (51%) patients with CD, 1051 (35%)
patients with UC, and 413 (14%) patients with either IBD-
unspecified or “IBD-unknown”. “IBD-unknown” included patients
who did not know their IBD subtype, reported UC with ileal
involvement or fistulas. As there were no significant differences
between patients with IBD-unknown/-unspecified and UC regard-
ing demographic (age, sex) and clinical characteristics (disease
duration, abdominal surgery, stoma, pouch, and medication use),
these groups were analyzed together (hereafter referred to as UC).
Three hundred seven (20%) out of 1551 patients with CD and
354 (24%) out of 1464 patients with UC were older than 60 years.
The proportion of patients lost to follow-up was compara-
ble between elderly and younger patients with IBD, namely
15.0% versus 15.4% (P ¼ 0.78). Both elderly and younger pa-
tients with IBD who were lost to follow-up were more likely to be
women (P ¼ 0.02), smoker (P, 0.01), and had a lower education
level (P, 0.01) than those patients with IBD who were not lost to
follow-up.
Elderly patients with CD were more likely to be men (P ,
0.01), had a higher probability of a positive history of abdominal
surgery (P , 0.01), and a current stoma (P , 0.01) compared
with younger patients with CD (Table 1). Younger patients with
CD were more likely to be smoker (P ¼ 0.01), had a higher
incidence of clinical active disease (P ¼ 0.01), and were more
frequently treated with immunosuppressants (P , 0.01) and anti-
TNFa antibodies (P , 0.01). Elderly patients with UC were more
likely to be men (P , 0.00) compared with younger patients with
UC (Table 2). Younger patients with UC had a higher incidence
of clinical active disease (P ¼ 0.01) and were more frequently
treated with immunosuppressants (P , 0.01) and anti-TNFa anti-
bodies (P ¼ 0.04).
DHC-IBD Costs in CD and UC
The mean DHC-IBD per patient per 3 months was lower in
elderly patients than in younger patients with IBD, i.e., €982
versus €1428 (P , 0.01) in CD and €637 versus €995 (P ,
0.01) in UC (Fig. 1). Medication use was the major cost driver
in both elderly patients with CD and UC, accounting for 62% and
60% of total DHC, respectively. The costs attributable to anti-
TNFa antibodies were consistently lower in elderly than in youn-
ger patients with IBD (€523 versus €962, P , 0.01 in CD and
€287 versus €608, P , 0.01 in UC).
In elderly CD, the only significant predictor of high costs
was anti-TNFa therapy (odds ratio [OR], 15.30; 95% CI, 12.61–
18.56). Significant predictors of high costs in elderly UC were
anti-TNFa therapy (OR, 18.70; 95% CI, 14.40–24.27), stoma
use (OR, 9.30; 95% CI, 6.51–13.29), steroid therapy (OR,
1.28; 95% CI, 1.10–1.49), immunosuppressive therapy (OR,
1.25; 95% CI, 1.10–1.42), and current flares (OR, 1.17; 95%
CI, 1.08–1.27).
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Productivity Losses and Out-of-pocket Costs
in CD and UC
Productivity losses due to sick leave of paid work were
lower in elderly patients than in younger patients with CD
and UC (€97 versus €420 [P ¼ 0.04] and €54 versus €392
[P , 0.01], respectively). Productivity losses due to sick
leave of unpaid work were higher in elderly than in
younger CD, but comparable between elderly and younger
patients with UC (€25 versus €14 [P , 0.01] and €22 versus
€20 [P ¼ 0.69], respectively). Out-of-pocket costs were
lower in elderly than in younger patients with CD and UC
(€48 versus €75 [P , 0.01] and €4 versus €37 [P , 0.01],
TABLE 1. Main Baseline Characteristics of Younger (,60 yr) Versus Elderly Patients ($60 yr) with CD
Younger CD, n ¼ 1244 Elderly CD, n ¼ 307 P
Demographic characteristics
Male gender (%) 408 (32.8) 164 (53.4) 0.00
Age (6SD), yr 42.2 (10.8) 66.0 (5.0) 0.00
Age at diagnosis (6SD), yr 26.7 (9.8) 40.2 (14.9) 0.00
Low education (%) 777 (62.5) 223 (72.6) 0.00
Positive family history (%) 265 (21.3) 71 (23.1) 0.50
Current smoker 279 (22.4) 49 (16.0) 0.01
Employment status (%)
Employed 706 (56.8) 31 (10.0) 0.00
Fully work disabled 153 (12.3) 22 (7.2) 0.01
Partially work disabled 208 (16.7) 55 (17.9) 0.62
Retired 7 (0.6) 173 (56.4) 0.00
Homemaker 108 (8.7) 26 (8.5) 0.91
Student 62 (5.0) — 0.00
Clinical characteristics
Disease duration, median (IQR) 13.9 (6.9–22.8) 24.9 (13.9–37.5) 0.00
Disease localization (%)
Large bowel 335 (26.9) 92 (30.0) 0.29
Small bowel 241 (19.4) 66 (21.5) 0.40
Both large and small bowel 630 (50.6) 134 (44.6) 0.03
Unknown 38 (3.1) 15 (4.9) 0.11
Clinical disease activity, mean score on short-CDAI 146.5 (85.2) 119.5 (69.7) 0.01
IBDQ total, median (IQR) 177 (153–196) 176 (155–198) 0.48
EQ-5D Visual Analogue Scale, median (IQR) 71 (61–80) 70 (60–80) 0.46
Penetrating disease course (%) 658 (52.9) 150 (48.9) 0.21
Stoma (%) 137 (11.0) 54 (17.6) 0.00
Pouch (%) 21 (1.7) 7 (2.3) 0.49
Treatment-related characteristics
Type of abdominal surgery in the past (%) 713 (57.3) 233 (75.9) 0.00
Ileocecal resection 281 (22.6) 79 (25.7) 0.17
Resection neo-terminal ileum 82 (6.6) 35 (11.4) 0.00
Partial small bowel resection 118 (9.5) 43 (14.0) 0.02
Partial large bowel resection 136 (10.9) 41 (13.4) 0.28
Subtotal resection 96 (7.7) 35 (11.4) 0.04
Medication use (%)a
Mesalazine 221 (21.4) 67 (25.1) 0.20
Steroids 81 (7.8) 26 (9.7) 0.32
Immunosuppressants 359 (34.6) 59 (22.1) 0.00
Anti-TNFa antibodies 262 (25.3) 35 (13.1) 0.00
aMedication use was obtained 3 months after inclusion. In total, 1035 younger patients with CD and 267 elderly patients with CD reported their medication use.
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respectively) (Fig. 2; see Tables, Supplemental Digital
Content 3 and 4, http://links.lww.com/IBD/A406 and
http://links.lww.com/IBD/A407).
DHC-IBD Costs in 2011
Costs were lower in elderly versus younger patients with
IBD with respect to 3-monthly DHC-IBD (€359 versus €978,
P , 0.01), productivity losses (€108 versus €456, P , 0.01),
and out-of-pocket costs (€40 versus €57, P , 0.01). Within
elderly patients with IBD, costs were higher in patients aged 60
to 70 years versus patients aged 70 years or older with respect
to DHC-IBD (€432 versus €241, P ¼ 0.000), productivity los-
ses (€119 versus €14, P ¼ 0.001), and out-of-pocket costs (€46
versus €19, P ¼ 0.001).
Projections of IBD Population and DHC-IBD
The total IBD population in the Netherlands is expected
to increase from 43,953 in 2011 to 46,894 individuals in 2040,
an increase of 7%. The total number of elderly patients with
IBD will increase from 10,658 in 2011 to 16,323 in 2040,
a growth of 53% (see Table, Supplemental Digital Content 1,
http://links.lww.com/IBD/A404).
According to our base-case analysis (population aging +
rising prizes + volume), the DHC-IBD of the total adult IBD
projection are projected to increase from €161 million to €661
million in 2040, a 4.1-fold increase. The contributions of popula-
tion aging, price inflation, and volume to this increase were
respectively 1%, 29%, and 70% (Fig. 3).
According to our scenario analysis (population aging +
rising prizes), the DHC-IBD of the total adult IBD projection
TABLE 2. Main Baseline Characteristics of Younger Patients (,60 yr) Versus Elderly Patients ($60 yr) with UC
Younger UCa, n ¼ 1110 Elderly UCa, n ¼ 354 P
Demographic characteristics
Male gender (%) 503 (45.3) 245 (69.2) 0.00
Age (6SD), yr 44.1 (10.3) 66.7 (5.6) 0.00
Age at diagnosis (6SD), yr 30.8 (10.8) 48.2 (14.0) 0.00
Low education (%) 647 (58.3) 239 (67.5) 0.02
Positive family history (%) 224 (20.2) 76 (21.5) 0.44
Current smoker 127 (11.4) 28 (7.9) 0.06
Employment status (%)
Employed 755 (68.0) 57 (16.1) 0.00
Fully work disabled 128 (11.5) 16 (4.5) 0.00
Partially work disabled 93 (8.4) 48 (13.6) 0.00
Retired 15 (1.4) 212 (59.9) 0.00
Homemaker 95 (8.6) 21 (5.9) 0.12
Student 24 (2.2) — 0.00
Clinical characteristics
Disease duration, median (IQR) 11.2 (5.9–19.9) 16.3 (6.9–28.9) 0.00
Clinical disease activity, mean score on MTWSI (6SD) 4.2 (2.8) 3.8 (2.4) 0.01
IBDQ total, median (IQR) 184 (160–202) 189 (166–204) 0.01
EQ-5D Visual Analogue Scale, median (IQR) 74 (65–81) 73 (65–80) 0.71
Stoma (%) 80 (7.2) 27 (7.6) 0.82
Pouch (%) 119 (10.7) 19 (5.4) 0.00
Treatment-related characteristics
Subtotal colectomy in the past (%) 126 (11.4) 23 (6.5) 0.01
Medication use (%)b
Mesalazine 551 (59.3) 197 (62.5) 0.35
Steroids 44 (4.7) 18 (5.7) 0.59
Immunosuppressants 205 (22.1) 47 (14.9) 0.00
Anti-TNFa antibodies 49 (5.3) 7 (2.2) 0.04
aIncluding patients with UC and patients with IBD-unspecified/“IBD-unknown.”
bMedication use was obtained 3 months after inclusion. In total, 929 younger UC patients and 315 elderly UC patients reported their medication use.
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are projected to increase from €161 million to €310 million in
2040, a 1.9-fold increase.
When using the low and high boundaries of the estimated
DHC-IBD and the IBD prevalence rates in our base-case analysis,
the projected DHC-IBD of the adult IBD population in 2040
varied between €559 and €763 million (Fig. 3) and between €580
and €741 million, respectively.
DISCUSSION
Healthcare costs have significantly increased over the
recent years. This has been attributed to an overall increase in
prices of healthcare expenditure, volume growth, and population
aging. The latter contributes to higher healthcare costs because of
the increasing likelihood of chronic illness with age and a general
increased healthcare utilization. In IBD, however, we found that
the impact of population aging on the DHC-IBD of the total adult
IBD population, presuming status quo in treatment, is mitigated
by 2 factors: (1) the relatively low healthcare utilization by elderly
patients with IBD and (2) a reduced proportion of relatively
expensive middle-aged (40–60 yr) patients with IBD due to the
declining birth rate since the baby boom.
COIN Cohort
Several reasons may explain the lower healthcare utiliza-
tion, productivity losses, and out-of-pocket costs in elderly
patients with IBD as compared with younger patients with IBD.
Consistent with previous studies, expensive anti-TNFa anti-
bodies were less frequently prescribed for elderly than for younger
patients with IBD,4,32–34 which may suggest a milder disease
course in elderly IBD patients. Accordingly, in our study, elderly
patients with IBD reported a lower disease activity at baseline and
a higher quality of life at baseline and during follow-up than
younger IBD patients (see Table, Supplemental Digital Content
5, http://links.lww.com/IBD/A408). A milder disease course, when
aged, has been reported by other authors showing lower require-
ments of immunosuppressants and anti-TNFa antibodies,33,35
reduced rates of hospitalization,36,37 and disease progression,35,38
and better treatment response.39 Additionally, clinicians may hes-
itate to prescribe anti-TNFa antibodies in elderly patients, because
of doubts related to the efficacy or the demonstrated increased risk
of potential side effects of these compounds in elderly, such as
(opportunistic) infections40,41 and cancer.42
Second, overall productivity losses were lower in elderly
than in younger patients with IBD, obviously because most
elderly patients with IBD were retired.
Third, most elderly patients with IBD were captured at
a later stage of their disease as reflected by the long median
disease duration and were therefore exempted from high costs that
are usually incurred in the first years after diagnosis.43,44
Projection of IBD-attributable DHC Until 2040
Productivity losses could not reliably be extrapolated due to
ongoing policy changes with respect to retirement age and were
therefore excluded. However, according to previous and current
FIGURE 1. Mean DHCs per 3 months in 2011 and cost drivers of both elderly and younger patients with both CD and UC. *P , 0.00, #Mean costs
per 3 months related to surgery were €2, €6, €4, and €6 for elderly patients with UC, younger patients with UC, elderly patients with CD, and
younger patients with CD, respectively.
FIGURE 2. Mean productivity losses and mean out-of-pocket costs per 3 months in 2011 of both elderly and younger patients with CD and UC. *P, 0.00.
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data, productivity losses contribute to only one-fourth of the total
healthcare costs.4 In line with recent data from high-incidence
countries showing a stabilization of the IBD prevalence, we
assumed that the current IBD prevalence would remain constant
for the next 30 years.3,45
Next to population aging, we assessed the impact of
increasing prices and volume on the growth of DHC-IBD, thereby
identifying potential targets for cost containment interventions
and putting the effect of population aging on the growing DHC-
IBD into perspective.
According to our projections, the DHC-IBD would qua-
druple from €161 million to €661 million between 2011 and 2040.
Only 1% of this growth is attributable to population aging. The
limited effect of population aging on the DHC-IBD is due to the
fact that elderly IBD patients use considerably less IBD-
attributable healthcare compared with their younger counterparts.
In addition, due to population aging the proportion of relative
costly middle-aged (40–60 yr) patients with IBD will reduce from
43% in 2011% to 35% in 2040.
Another important finding was that 70% of the growth in
DHC-IBD is attributable to volume. We suggest that technolog-
ical innovations, frequently cited as a major volume-generating
factor,46,47 are mainly responsible for this growth. In IBD, bio-
logicals are considered important technological innovations. The
expanding indications for the use of existing biologicals (mainly
anti-TNFa antibodies) and the introduction of new compounds48
may generate additional volume and, thereby, increase the DHC-
IBD even more. Although biosimilars, that are generally priced
15% to 30% below their reference products, may reduce the total
costs related to the use of biologicals/biosimilars,49–51 in our opin-
ion, this will likely have a minor effect on the expected utilization
of these compounds in the future.
The future healthcare utilization of elderly patients with
IBD might increase for several reasons. First, as younger patients
with IBD will continue to use expensive biologicals while they
age, more elderly patients with IBD may be expected to use these
compounds in the future. Second, as experience with the use of
biologicals in elderly IBD patients grows, clinicians may be less
concerned about potential side effects and prescribe biologicals
more frequently. Whether this increased healthcare utilization
would disproportionately affect elderly patients with IBD remains
a matter of debate, and if so, the effect of population aging on
DHC as we reported might be underestimated. However, we feel
that more aggressive or treat-to-target treatment of younger
patients with IBD will also lead to a higher healthcare utilization
in this subpopulation, which will counterbalance the potential
increase in healthcare utilization in elderly patients with IBD.
This study has several limitations. First, the web-based
design of this study may be prone to sampling error, as elderly
people may have a relatively limited access to Internet. However,
since 90% of elderly people in the Netherlands currently have
access to Internet,52 we do not feel that this aspect has biased our
study. Second, our projections may be subject to sampling error as
our prevalence rates were based on information from a health
insurance database.53 Yet, coding errors in this database are reg-
ularly excluded by random checks and auditing,28 and prevalence
rates are consistent with those from surrounding countries in
Europe and North America.54,55 Third, attrition bias may have
FIGURE 3. Projections of DHC-IBD costs in the Dutch adult population from 2011 to 2040, considering the cumulative effects of population aging,
rising prices, and volume growth. #The dotted lines represent the one-way sensitivity analysis, using the upper and lower boundaries of only the
mean DHC-IBD.
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occurred as patients who were lost to follow-up were more likely
to be women, smokers, and had a lower education. Nevertheless,
none of these characteristics were found to be significantly asso-
ciated with higher costs. Fourth, indirect costs resulting from
polypharmacy, drug-drug interactions or side effects of medica-
tions might have been missed. This may have led to an underes-
timation of total indirect healthcare costs, especially of those in
elderly patients with IBD.
This study provides valuable information on current and
future healthcare costs of elderly patients with IBD that will be
useful to (1) inform decision makers as they plan to meet future
healthcare demands in the elderly in general and (2) provide cost
data to assess the cost-effectiveness of treatment strategies in
elderly patients with IBD.
In conclusion, although population aging is generally con-
sidered an important cost driver, this does not hold true for IBD. In
IBD, the impact of aging is mitigated, because of the lower ratio of
DHC-IBD for elderly versus younger patients. This lower ratio may
also be found in other immune-mediated inflammatory diseases such
as rheumatoid arthritis, where elderly patients are also less likely to
receive expensive biological treatment.56,57 Therefore, we feel that
our data may be generalizable to other immune-mediated inflamma-
tory diseases. Further comparative cost-of-illness studies are needed
to confirm this state statement.
ACKNOWLEDGMENTS
Author contributions: M. van der Have had full access to all
data in the study and takes responsibility for the integrity of the
data and the accuracy of the data analysis; study concept
and design: M. E. van der Valk, B. Oldenburg, M-J. J. Mangen,
M. E. van der Have; patient enrollment: A. van Bodegraven,
G. Dijkstra, H. H. Fidder, D. J. de Jong, Pierik, C. Y. Ponsioen,
A. E. van der Meulen-de Jong, C. J. van der Woude, P. C. van de
Meeberg, M. J. L. Romberg-Camps, C. H. M. Clemens,
J. M. Jansen, N. Mahmmod, C. J. M. Bolwerk, J. R. Vermeijden;
acquisition of data: M. van der Have, B. Oldenburg, M-J.
J. Mangen; drafting of manuscript: M. van der Have; analysis
and interpretation of data: M. van der Have, B. Oldenburg, M-J.
J. Mangen, H. H. Fidder; critical revision of the manuscript: All
authors; statistical analysis: M. Leenders, M-J. J. Mangen, M. van
der Have; study supervision: B. Oldenburg.
REFERENCES
1. Jacobsen BA, Fallingborg J, Rasmussen HH, et al. Increase in incidence
and prevalence of inflammatory bowel disease in northern Denmark:
a population-based study, 1978–2002. Eur J Gastroenterol Hepatol.
2006;18:601–606.
2. Lapidus A. Crohn’s disease in Stockholm County during 1990–2001: an
epidemiological update. World J Gastroenterol. 2006;12:75–81.
3. Loftus CG, Loftus EV Jr, Harmsen WS, et al. Update on the incidence and
prevalence of Crohn’s disease and ulcerative colitis in Olmsted County,
Minnesota, 1940-2000. Inflamm Bowel Dis. 2007;13:254–261.
4. Van der Valk ME, Mangen MJ, Leenders M; on behalf COIN study group
and the Dutch Initiative on Crohn and Colitis. Healthcare costs of inflam-
matory bowel disease have shifted from hospitalisation and surgery towards
anti-TNFa therapy: results from the COIN study. Gut. 2014;63:72–79.
5. Piront P, Louis E, Latour P, et al. Epidemiology of inflammatory bowel
diseases in the elderly in the province of Leige. Gastroenterol Clin Biol.
2002;26:157–161.
6. Proj_10c2150p [databae online] Giampaolo Lanzieri: Eurostat, statistical
office of the European Union; 2012. Update March 6, 2012.
7. Page MJ, Poritz LS, Kunselman SJ, et al. Factors affecting surgical risk in
elderly patients with inflammatory bowel disease. J Gastrointest Surg.
2002;6:606–613.
8. Ananthakrishnan AN, McGinley EL, Binion DG. Inflammatory bowel
disease in the elderly is associated with worse outcomes: a national study
of hospitalizations. Inflamm Bowel Dis. 2009;15:182–189.
9. Kaplan RM, Babad YM. Balancing influence between actors in healthcare
decision making. BMC Health Serv Res. 2011;11:85.
10. Hay JW, Hay AR. Inflammatory bowel disease: costs-of-illness. J Clin
Gastroenterol. 1992;14:309–317.
11. Hay AR, Hay JW. Inflammatory bowel disease: medical cost algorithms.
J Clin Gastroenterol. 1992;14:318–327.
12. Blomqvist P, Ekbom A. Inflammatory bowel diseases: health care and
costs in Sweden in 1994. Scand J Gastroenterol. 1997;32:1134–1139.
13. Bernstein CN, Papineau N, Zajaczkowski J, et al. Direct hospital costs for
patients with inflammatory bowel disease in a Canadian Tertiary Care
University Hospital. Am J Gastroenterol. 2000;95:677–683.
14. Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs
of care for Crohn’s disease: Markov model analysis of a population-based
cohort. Gastroenterology. 1999;117:49–57.
15. Bassi A, Dodd S, Williamson P, et al. Cost of illness of inflammatory
bowel disease in the UK: a single centre retrospective study. Gut. 2004;
53:1471–1478.
16. Odes S, Vardi H, Friger M, et al. Cost analysis and cost determinants in
a European inflammatory bowel disease inception cohort with 10 years of
follow-up evaluation. Gastroenterology. 2006;131:719–728.
17. Enthoven AC, van de Ven WP. Going Dutch—managed-competition
health insurance in the Netherlands. N Engl J Med. 2007;357:2421–2423.
18. Tsiachristas A, Hipple-Walters B, Lemmens KM, et al. Towards inte-
grated care for chronic conditions: Dutch policy developments to over-
come the (financial) barriers. Health Policy. 2011;101:122–132.
19. Van Schaik FD, van Oijen MG, Smeets HM, et al. Thiopurines prevent
advanced colorectal neoplasia in patients with inflammatory bowel dis-
ease. Gut. 2012;61:235–240.
20. Baars JE, Looman CW, Steyerberg EW, et al. The risk of inflammatory
bowel disease-related colorectal carcinoma is limited: results from
a nationwide nested case-control study. Am J Gastroenterol. 2011;
106:319–328.
21. Timmer A, Kemptner D, Takses A, et al. A survey based index was
validated for measuring disease activity in inflammatory bowel disease.
An evaluation study. J Clin Epidemiol. 2009;62:771–778.
22. Lichtiger S, Present DH. Preliminary report: cyclosporin in treatment of
severe active ulcerative colitis. Lancet. 1990;336:16–19.
23. Truelove SC, Witts LJ. Cortisone and corticotrophin in ulcerative colitis.
Br Med J. 1959;1:387–394.
24. Salén BA, Spangfort EV, Nygren AL, et al. The disability rating index: an
instrument for the assessment of disability in clinical settings. J Clin
Epidemiol. 1994;47:1423–1435.
25. König HH, Ulshöfer A, Gregor M, et al. Validation of the EuroQol ques-
tionnaire in patients with inflammatory bowel disease. Eur J Gastroenterol
Hepatol. 2002;14:1205–1215.
26. Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for
clinical trials in inflammatory bowel disease. Gastroenterology. 1989;96:
804–810.
27. Russel MG, Pastoor CJ, Brandon S, et al. Validation of the Dutch
translation of the inflammatory bowel disease questionnaire (IBDQ):
a health-related quality of life questionnaire in inflammatory bowel dis-
ease. Digestion. 1997;58:282–288.
28. Hakkaart-van Roijen L. Manual for Costing: Methods and Reference
Prices for Economic Evaluations in Healthcare [Health Care Insurance





Handleiding+voor+kostenonderzoek.pdf. Accessed June 9, 2013.
van der Have et al Inflamm Bowel Dis  Volume 20, Number 4, April 2014
644 | www.ibdjournal.org
29. Smeets HM, de Wit NJ, Hoes AW. Routine health insurance data for
scientific research: potential and limitations of the Agis Health Database.
J Clin Epidemiol. 2011;64:424–430.
30. Prognosis census; gender, age, country of origin and generation, 2013-
2060 [Database online]. Joop Beer: Statistical office of the Netherlands;
2012. Updated December 13, 2012.
31. Consumer prices; price index 2006 ¼ 100 [Database online]. Joop Beer:
Statistical office of the Netherlands; 2012. Update January 9, 2014.
32. Luijben AHP, Kommer GJ. Tijd en Toekomst. Deelrapport van de Volksge-
zondheid Toekomst Verkenning 2010 Van Gezond naar Beter. RIVM-rapport
270061008. Bilthoven, the Netherlands: RIVM; 2010.
33. Juneja M, Baidoo L, Schwartz MB, et al. Geriatric inflammatory bowel
disease: phenotypic presentation, treatment patterns, nutritional status,
outcomes, and comorbidity. Dig Dis Sci. 2012;57:2408–2415.
34. Benchimol EI, Cook SF, Erichsen R, et al. International variation in
medication prescription rates among elderly patients with inflammatory
bowel disease. J Crohns Colitis. 2013;7:878–889.
35. Charpentier C, Salleron J, Savoye G, et al. Natural history of elderly-onset
inflammatory bowel disease: a population-based cohort study. Gut. 2014;63:
423–432.
36. Kappelman MD, Porter CQ, Galanko JA, et al. Utilization of healthcare
resources by U.S. children and adults with inflammatory bowel disease.
Inflamm Bowel Dis. 2011;17:62–68.
37. Heresbach D, Alexandre JL, Bretagne JF, et al. Crohn’s disease in
the over-60 age group: a population based study. Eur J Gastroenterol
Hepatol. 2004;16:657–664.
38. Lakatos PL, David G, Pandur T, et al. IBD in the elderly population:
results from a population-based study in Western Hungary, 1977-2008.
J Crohns Colitis. 2011;5:5–13.
39. Ha CY, Newberry RD, Stone CD, et al. Patients with late-adult-onset
ulcerative colitis have better outcomes than those with early onset disease.
Clin Gastroenterol Hepatol. 2010;8:682–687.e1.
40. Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent
risk factor for severe infections and mortality in patients given anti-tumor
necrosis factor therapy for inflammatory bowel disease. Clin Gastroenter-
ol Hepatol. 2011;9:30–35.
41. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic
infections in patients with inflammatory bowel disease. Gastroenterology.
2008;134:929–936.
42. Siegel CA, Hur C, Korzenik JR, et al. Risks and benefits of infliximab for
the treatment of Crohn’s disease. Clin Gastroenterol Hepatol. 2006;4:
1017–1024.
43. Bernstein CN, Longobardi T, Finlayson G, et al. Direct medical cost of
managing IBD patients: a Canadian population-based study. Inflamm
Bowel Dis. 2012;18:1498–1508.
44. Longobardi T, Bernstein CN. Utilization of health-care resources by
patients with IBD in Manitoba: a profile of time since diagnosis. Am J
Gastroenterol. 2007;102:1683–1691.
45. Kappelman MD, Moore KR, Allen JK, et al. Recent trends in the prev-
alence of Crohn’s disease and ulcerative colitis in a commercially insured
US population. Dig Dis Sci. 2013;58:519–525.
46. Okunade AA, Murthy VNR. Technology as ‘major driver’ of health care
costs: a cointegration analysis of the newhouse conjecture. J Health Econ.
2002;21:147–159.
47. Gelijns A, Rosenberg N. The dynamics of technological change in med-
icine. Health Aff (Millwood). 1994;13:28–46.
48. Danese S. New therapies for inflammatory bowel disease: from the bench
to the bedside. Gut. 2012;61:918–932.
49. Gecse KB, Khanna R, van den Brink GR, et al. Biosimilars in IBD:
hope or expectation? Gut. 2013;62:803–807.
50. Malik NN. Controlling the cost of innovative cancer therapeutics. Nat Rev
Clin Oncol. 2009;6:550–552.
51. Keith J. Fontenot. S1695: biologics price competition and innovation Act
of 2007 Congressional Budget Office cost estimate [Congressional Budget
Office Website]. June 25, 2008. Available at: http://www.cbo.gov/ftpdocs/
94xx/doc9496/s1695.pdf. Accessed June 9, 2013.
52. Sleijpen G. Home Internet access rate highest in the Netherlands [Statistical
office of the Netherlands, Website]. June 18, 2012. Available at: http://
www.cbs.nl/enGB/menu/themas/dossiers/eu/publicaties/archief/2012/2012-
3636-wm.htm. Accessed June 9, 2013.
53. Wilchesky M, Tamblyn RM, Huang A. Validation of diagnostic codes
within medical services claims. J Clin Epidemiol. 2004;57:131–141.
54. Burisch J, Jess T, Martinato M, et al; on behalf of ECCO -EpiCom. The
burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013;7:
322–337.
55. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: inci-
dence, prevalence, and environmental influences. Gastroenterology. 2004;
126:1504–1517.
56. Radovits BJ, Fransen J, Eijsbouts A, et al. Missed opportunities in the
treatment of elderly patients with rheumatoid arthritis. Rheumatology
(Oxford). 2009;48:906–910.
57. Tutuncu Z, Reed G, Kremer J, et al. Do patients with older-onset rheu-
matoid arthritis receive less aggressive treatment? Ann Rheum Dis. 2006;
65:1226–1229.
Inflamm Bowel Dis  Volume 20, Number 4, April 2014 Effect of Aging on Healthcare Costs of IBD
www.ibdjournal.org | 645
